In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity

Nature Biotechnology

Volumn 33, Issue 11, 2015, Pages 1201-1210

  Lynn, Geoffrey M ^a,b   Laga, Richard ^b,c   Darrah, Patricia A ^a   Ishizuka, Andrew S ^a   Balaci, Alexandra J ^a   Dulcey, Andrés E ^d   Pechar, Michal ^c   Pola, Robert ^c   Gerner, Michael Y ^a   Yamamoto, Ayako ^a   Buechler, Connor R ^a   Quinn, Kylie M ^a   Smelkinson, Margery G ^a   Vanek, Ondrej ^e   Cawood, Ryan ^b   Hills, Thomas ^b   Vasalatiy, Olga ^d   Kastenmüller, Kathrin ^a   Francica, Joseph R ^a   Stutts, Lalisa ^f   Tom, Janine K ^f   Ryu, Keun Ah ^f   Esser Kahn, Aaron P ^f   Etrych, Tomas ^c   Fisher, Kerry D ^b   Seymour, Leonard W ^b   Seder, Robert A ^b   more..

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c INSTITUTE OF MACROMOLECULAR CHEMISTRY   (Czech Republic)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^e CHARLES UNIVERSITY   (Czech Republic)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES; ANTIGENS; HYDROGELS; PROTEINS; T-CELLS; VACCINES;

PARTICLE FORMATIONS; PHARMACOKINETIC PROFILES; PHYSICOCHEMICAL PROPERTY; PHYSIOLOGIC TEMPERATURE; POLYMER SCAFFOLDS; TEMPERATURE RESPONSIVE POLYMERS; TOLL-LIKE RECEPTORS; VACCINE ADJUVANTS;

POLYMERS;

POLYMER; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR AGONIST; VACCINE; DRUG CARRIER; IMMUNOLOGICAL ADJUVANT; TOLL LIKE RECEPTOR;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; ARTICLE; BIOCOMPATIBILITY; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG SYNTHESIS; FEMALE; IMMUNOGENICITY; IN VIVO STUDY; INNATE IMMUNITY; MALE; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; TEMPERATURE; AGONISTS; ANIMAL; C57BL MOUSE; CHEMISTRY; IMMUNOLOGY; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; DRUG CARRIERS; FEMALE; MALE; MICE; MICE, INBRED C57BL; T-LYMPHOCYTES; TOLL-LIKE RECEPTORS; VACCINES;

EID: 84946572121     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.3371     Document Type: Article

References (58)

1. Plotkin, S.A. Correlates of protection induced by vaccination. Clin. Vaccine Immunol. 17, 1055-1065 (2010).
2. Epstein, J.E. et al. Live attenuated malaria vaccine designed to protect through hepatic CD8+ T cell immunity. Science 334, 475-480 (2011).
3. Andersen, P. and Woodworth, J.S. Tuberculosis vaccines-rethinking the current paradigm. Trends Immunol. 35, 387-395 (2014).
4. Arens, R., van Hall, T., van der Burg, S.H., Ossendorp, F. and Melief, C.J. Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer. Semin. Immunol. 25, 182-190 (2013).
5. Guy, B. The perfect mix: recent progress in adjuvant research. Nat. Rev. Microbiol. 5, 505-517 (2007).
6. Iwasaki, A. and Medzhitov, R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5, 987-995 (2004).
7. Nordly, P., Madsen, H.B., Nielsen, H.M. and Foged, C. Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators. Expert Opin. Drug Deliv. 6, 657-672 (2009).
8. Brito, L.A. and O'Hagan, D.T. Designing and building the next generation of improved vaccine adjuvants. J. Control. Release 190C, 563-579 (2014).
9. Fox, C.B. et al. TLR4 ligand formulation causes distinct effects on antigen-specific cell-mediated and humoral immune responses. Vaccine 31, 5848-5855 (2013).
10. Wille-Reece, U. et al. HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc. Natl. Acad. Sci. USA 102, 15190-15194 (2005).
11. Shukla, N.M. et al. Toward self-adjuvanting subunit vaccines: model peptide and protein antigens incorporating covalently bound toll-like receptor-7 agonistic imidazoquinolines. Bioorg. Med. Chem. Lett. 21, 3232-3236 (2011).
12. Wu, C.C. et al. Immunotherapeutic activity of a conjugate of a Toll-like receptor 7 ligand. Proc. Natl. Acad. Sci. USA 104, 3990-3995 (2007).
13. Kasturi, S.P. et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470, 543-547 (2011).
14. Jewell, C.M., Lopez, S.C. and Irvine, D.J. In situ engineering of the lymph node microenvironment via intranodal injection of adjuvant-releasing polymer particles. Proc. Natl. Acad. Sci. USA 108, 15745-15750 (2011).
15. Ilyinskii, P.O. et al. Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release. Vaccine 32, 2882-2895 (2014).
16. Moon, J.J. et al. Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction. Proc. Natl. Acad. Sci. USA 109, 1080-1085 (2012).
17. Smirnov, D., Schmidt, J.J., Capecchi, J.T. and Wightman, P.D. Vaccine adjuvant activity of 3M-052: an imidazoquinoline designed for local activity without systemic cytokine induction. Vaccine 29, 5434-5442 (2011).
18. Liu, H. et al. Structure-based programming of lymph-node targeting in molecular vaccines. Nature 507, 519-522 (2014).
19. Wu, T.Y. et al. Rational design of small molecules as vaccine adjuvants. Sci. Transl. Med. 6, 263ra160 (2014).
20. Bachmann, M.F. and Jennings, G.T. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 10, 787-796 (2010).
21. Manolova, V. et al. Nanoparticles target distinct dendritic cell populations according to their size. Eur. J. Immunol. 38, 1404-1413 (2008).
22. Reddy, S.T., Rehor, A., Schmoekel, H.G., Hubbell, J.A. and Swartz, M.A. In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J. Control. Release 112, 26-34 (2006).
23. Kourtis, I.C. et al. Peripherally administered nanoparticles target monocytic myeloid cells, secondary lymphoid organs and tumors in mice. PLoS ONE 8, e61646 (2013).
24. Gorden, K.B. et al. Synthetic TLR Agonists reveal functional differences between human TLR7 and TLR8. J. Immunol. 174, 1259-1268 (2005).
25. Oh, J.Z., Kurche, J.S., Burchill, M.A. and Kedl, R.M. TLR7 enables cross-presentation by multiple dendritic cell subsets through a type I IFN-dependent pathway. Blood 118, 3028-3038 (2011).
26. Coffman, R.L., Sher, A. and Seder, R.A. Vaccine adjuvants: putting innate immunity to work. Immunity 33, 492-503 (2010).
27. Gerster, J.F. et al. Synthesis and structure-activity-relationships of 1H-imidazo[4,5-c]quinolines that induce interferon production. J. Med. Chem. 48, 3481-3491 (2005).
28. A, A.G., Tyring, S.K. and Rosen, T. Beyond a decade of 5% imiquimod topical therapy. J. Drugs Dermatol. 8, 467-474 (2009).
29. Savage, P. et al. A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily. Br. J. Cancer 74, 1482-1486 (1996).
30. Pockros, P.J. et al. Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies. J. Hepatol. 47, 174-182 (2007).
31. Seymour, L.W. et al. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J. Clin. Oncol. 20, 1668-1676 (2002).
32. Liu, X.M., Miller, S.C. and Wang, D. Beyond oncology-application of HPMA copolymers in non-cancerous diseases. Adv. Drug Deliv. Rev. 62, 258-271 (2010).
33. Seymour, L.W., Duncan, R., Strohalm, J. and Kopecek, J. Effect of molecular weight (Mbarw) of N-(2-hydroxypropyl)methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal, and intravenous administration to rats. J. Biomed. Mater. Res. 21, 1341-1358 (1987).
34. Sharp, F.A. et al. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc. Natl. Acad. Sci. USA 106, 870-875 (2009).
35. Russo, C. et al. Small molecule Toll-like receptor 7 agonists localize to the MHC class II loading compartment of human plasmacytoid dendritic cells. Blood 117, 5683-5691 (2011).
36. Ryu, K.A., Stutts, L., Tom, J.K., Mancini, R.J. and Esser-Kahn, A.P. Stimulation of innate immune cells by light-activated TLR7/8 agonists. J. Am. Chem. Soc. 136, 10823-10825 (2014).
37. Shakya, A.K., Holmdahl, R., Nandakumar, K.S. and Kumar, A. Characterization of chemically defined poly-N-isopropylacrylamide based copolymeric adjuvants. Vaccine 31, 3519-3527 (2013).
38. Shi, H.S. et al. Novel vaccine adjuvant LPS-Hydrogel for truncated basic fibroblast growth factor to induce antitumor immunity. Carbohydr. Polym. 89, 1101-1109 (2012).
39. Chou, H.Y. et al. Hydrogel-delivered GM-CSF overcomes nonresponsiveness to hepatitis B vaccine through the recruitment and activation of dendritic cells. J. Immunol. 185, 5468-5475 (2010).
40. Blander, J.M. and Medzhitov, R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 440, 808-812 (2006).
41. Nair-Gupta, P. et al. TLR signals induce phagosomal MHC-I delivery from the endosomal recycling compartment to allow cross-presentation. Cell 158, 506-521 (2014).
42. Jing, P., Rudra, J.S., Herr, A.B. and Collier, J.H. Self-assembling peptide-polymer hydrogels designed from the coiled coil region of fibrin. Biomacromolecules 9, 2438-2446 (2008).
43. Pechar, M. and Pola, R. The coiled coil motif in polymer drug delivery systems. Biotechnol. Adv. 31, 90-96 (2013).
44. Kastenmuller, K. et al. Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets. J. Clin. Invest. 121, 1782-1796 (2011).
45. Vecchi, S. et al. Conjugation of a TLR7 agonist and antigen enhances protection in the S. pneumoniae murine infection model. Eur. J. Pharm. Biopharm. 87, 310-317 (2014).
46. Scott, E.A. et al. Dendritic cell activation and T cell priming with adjuvant- and antigen-loaded oxidation-sensitive polymersomes. Biomaterials 33, 6211-6219 (2012).
47. Liu, H., Kwong, B. and Irvine, D.J. Membrane anchored immunostimulatory oligonucleotides for in vivo cell modification and localized immunotherapy. Angew. Chem. Intl. Edn. Engl. 50, 7052-7055 (2011).
48. Krieg, A.M. and Stein, C.A. Phosphorothioate oligodeoxynucleotides: antisense or anti-protein? Antisense Res. Dev. 5, 241 (1995).
49. Lahoud, M.H. et al. DEC-205 is a cell surface receptor for CpG oligonucleotides. Proc. Natl. Acad. Sci. USA 109, 16270-16275 (2012).
50. de Titta, A. et al. Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose. Proc. Natl. Acad. Sci. USA 110, 19902-19907 (2013).
51. Shukla, N.M., Malladi, S.S., Mutz, C.A., Balakrishna, R. and David, S.A. Structure-activity relationships in human toll-like receptor 7-active imidazoquinoline analogs. J. Med. Chem. 53, 4450-4465 (2010).
52. Hruby, M. et al. New bioerodable thermoresponsive polymers for possible radiotherapeutic applications. J. Control. Release 119, 25-33 (2007).
53. Subr, V. and Ulbrich, K. Synthesis and properties of new N-(2-hydroxypropyl)-methacrylamide copolymers containing thiazolidine-2-thione reactive groups. React. Funct. Polym. 66, 1525-1538 (2006).
54. Skeiky, Y.A. et al. Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant. Vaccine 20, 3292-3303 (2002).
55. Gerner, M.Y., Kastenmuller, W., Ifrim, I., Kabat, J. and Germain, R.N. Histo-cytometry: a method for highly multiplex quantitative tissue imaging analysis applied to dendritic cell subset microanatomy in lymph nodes. Immunity 37, 364-376 (2012).
56. Quinn, K.M. et al. Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization. J. Immunol. 190, 2720-2735 (2013).
57. Darrah, P.A. et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med. 13, 843-850 (2007).
58. Seder, R.A., Darrah, P.A. and Roederer, M. T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol. 8, 247-258 (2008).